| Patient | Franklin D. Roosevelt |
|---|---|
| Date of birth | 1882-01-30 |
| Identifiers | MRN HR-ET002-SYN-TD; SSN (made up) 000-02-5130 |
| Document date | 1944-06-26 |
| Author | Nathaniel Brooks, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three-month heart failure and blood pressure review. [S]
Mr. Roosevelt returns for his three-month review. He propels his wheelchair on level ground without stopping and is breathless only on long ramps. He sleeps on one pillow and has had no leg swelling for several weeks. His home weights have held at 83 to 84 kg for a month, and his home blood pressures run in the 120s over 70s. He felt more energetic within a few weeks of the iron infusions and is working full days again. He has had no lightheadedness on transfers, no breast tenderness on spironolactone, and no muscle aches on atorvastatin. He has not smoked since April, cravings are now rare, and he asks to stop the patch. [S]
| Element | Detail |
|---|---|
| Interval change | Level ground without stopping; breathless only on long ramps; one pillow; no edema |
| Weight log | Stable at 83 to 84 kg for a month |
| Home blood pressure | 120s over 70s |
| Medication tolerance | No lightheadedness, breast tenderness, or muscle aches |
| Function | Working full days again |
| Tobacco | No cigarettes since April; rare cravings |
| NYHA class | II |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | More energy since the iron infusions; no fever |
| Cardiovascular | Negative | No chest pain, palpitations, orthopnea, or leg swelling |
| Respiratory | Positive | Breathless only on long ramps; morning cough fading |
| Genitourinary | Negative | No dysuria or genital itching |
| Neurological | Negative | No lightheadedness on transfers |
| Musculoskeletal | Negative | No muscle aches or cramps |
| Psychiatric | Negative | Mood good; PHQ-2 score 0 |
7 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Sacubitril 24 mg / valsartan 26 mg oral tablet, one tablet by mouth twice daily | One tablet by mouth twice daily | Oral route | 1944-03-27 to 1944-04-10 | completed | S |
| Sacubitril 49 mg / valsartan 51 mg oral tablet, one tablet by mouth twice daily | One tablet by mouth twice daily | Oral route | 1944-04-10 | active | S |
| Carvedilol 3.125 mg oral tablet, one tablet by mouth twice daily with food | One tablet by mouth twice daily with food | Oral route | 1944-03-27 to 1944-04-10 | completed | S |
| Carvedilol 6.25 mg oral tablet, one tablet by mouth twice daily with food | One tablet by mouth twice daily with food | Oral route | 1944-04-10 to 1944-06-26 | completed | S |
| Carvedilol 12.5 mg oral tablet, one tablet by mouth twice daily with food | One tablet by mouth twice daily with food | Oral route | 1944-06-26 | active | S |
| Spironolactone 25 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1944-04-10 | active | S |
| Empagliflozin 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1944-03-27 | active | S |
| Furosemide 20 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1944-03-27 to 1944-06-26 | completed | S |
| Atorvastatin 40 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1944-03-27 | active | S |
| Nicotine 21 mg/24 hr transdermal patch, apply one patch daily | Apply one patch to the skin daily | Topical route | 1944-03-27 to 1944-06-26 | completed | S |
| Ferric carboxymaltose 750 mg in 15 mL intravenous infusion, two doses one week apart | 750 mg intravenously, two doses one week apart | Intravenous route | 1944-04-10 to 1944-04-17 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1944-06-26 | Body height | 188 | cm | S |
| 1944-06-26 | Body weight | 83 | kg | S |
| 1944-06-26 | Body mass index (BMI) [Ratio] | 23.5 | kg/m2 | S |
| 1944-06-26 | Systolic blood pressure | 128 | mm[Hg] | S |
| 1944-06-26 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1944-06-26 | Heart rate | 70 | /min | S |
| 1944-06-26 | Respiratory rate | 16 | /min | S |
| 1944-06-26 | Body temperature | 36.7 | Cel | S |
| 1944-06-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1944-06-26 | Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma | 980 | pg/mL | <=125 pg/mL | High | S |
| 1944-06-26 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 1944-06-26 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1944-06-26 | Creatinine [Mass/volume] in Serum or Plasma | 1.24 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1944-06-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1939)/1.73 sq M | 66 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1944-06-26 | Glucose [Mass/volume] in Serum or Plasma | 96 | mg/dL | 70-99 mg/dL | Normal | S |
| 1944-06-26 | Hemoglobin [Mass/volume] in Blood | 13.6 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 1944-06-26 | Ferritin [Mass/volume] in Serum or Plasma | 236 | ng/mL | 30-400 ng/mL | Normal | S |
| 1944-06-26 | Iron saturation [Mass Fraction] in Serum or Plasma | 27 | % | 20-50% | Normal | S |
| 1944-06-26 | Overall summary score [KCCQ-12] | 64 | {score} | S | ||
| 1944-06-26 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S |
Vital signs recorded on 1944-06-26; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well and energetic; weight 83 kg on the wheelchair scale |
| Neck | Jugular venous pressure 6 cm |
| Lungs | Clear |
| Heart | Regular rhythm, rate 70; no S3 |
| Chest | No breast enlargement or tenderness |
| Extremities | No edema |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Hypertensive heart disease with heart failure; synthetic modern diagnosis linked to the documented 1862 findings | active | confirmed | I11.0 | S — Synthetic active diagnosis for the teaching episode; the 1944 findings remain D. |
| Heart failure with reduced ejection fraction, NYHA class III at diagnosis | active | confirmed | I50.22 | S — Synthetic diagnosis confirmed by echocardiogram in the modern episode. |
| Nicotine dependence, cigarettes | active | confirmed | F17.210 | S — Synthetic modern diagnosis linked to documented cigarette smoking. |
| Iron deficiency anemia in heart failure, repleted with intravenous iron | resolved | confirmed | D50.9 | S — Synthetic finding that echoes the documented 1941 anemia; the modern values are S. |
| Paraplegia from a paralytic illness at age 39, historically diagnosed as poliomyelitis; cause retrospectively disputed | active | provisional | B91 | S — Synthetic modern coding of the documented diagnosis; the alternative cause remains R. |
| Prediabetes | active | confirmed | R73.03 | S — Synthetic finding from the baseline HbA1c. |
| Hyperlipidemia | active | confirmed | E78.5 | S — Synthetic finding from the baseline LDL cholesterol. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Basic metabolic panel | 1 to 2 weeks after starting or changing sacubitril/valsartan, spironolactone, empagliflozin, or a diuretic; every 3 to 6 months when stable | Completed today | Potassium 4.6, creatinine 1.24 mg/dL, eGFR 66. This is the first panel since sacubitril/valsartan was increased and spironolactone started eleven weeks ago |
| Laboratory | Basic metabolic panel 1 to 2 weeks after the April changes | Once, after titrating sacubitril/valsartan and starting spironolactone | Deferred | Not drawn in the window: the panel planned for the second iron infusion was not done, a deviation from the protocol. Today's potassium and kidney function are normal, so no harm resulted. Corrective action: each medication change now comes with a dated laboratory appointment booked before he leaves |
| Laboratory | Basic metabolic panel after stopping furosemide | 1 to 2 weeks after a diuretic change | Due | Furosemide stops today while he continues spironolactone and sacubitril/valsartan, which can raise potassium |
| Laboratory | NT-proBNP | Selectively in outpatient follow-up | Completed today | 980 pg/mL, down from 2850; informs decongestion and prognosis, not used to titrate therapy |
| Laboratory | Hemoglobin, ferritin, and transferrin saturation | 6 to 8 weeks after intravenous iron; then yearly | Completed today | Hemoglobin 13.6, ferritin 236, transferrin saturation 27 percent: repleted. Drawn ten weeks after the second dose, two weeks after the window, as planned in April; repletion is confirmed, so the delay caused no harm |
| Laboratory | Lipid panel | 4 to 12 weeks after starting a statin | Deferred | Not drawn in the window, which closed last week, and not on today's order, a deviation from the lipid protocol. He takes every dose and has no muscle symptoms, and a three-month delay in confirming the response carries little risk. Corrective action: added to the six-month laboratory order |
| Examination | Blood pressure, heart rate, weight, jugular venous pressure, edema, lungs | Every visit; every 1 to 2 weeks during titration | Completed today | Euvolemic at 83 kg |
| Survey | NYHA functional class | Every visit | Completed today | Class II |
| Survey | KCCQ-12 | Every 3 to 6 months | Completed today | 64, up 26 points from baseline |
| Survey | Depression screen (PHQ-2) | Periodically | Completed today | Score 0 |
| Imaging | Transthoracic echocardiogram | 3 to 6 months after therapy is optimized | Due | Planned for the six-month review, three months after today's carvedilol step |
| Imaging | 12-lead ECG | At initial evaluation; repeat with device consideration | Due | Still not on file (deviation recorded in April); needed before the device decision at the six-month review |
| Referral | Cardiac rehabilitation | Ejection fraction 35 percent or less, NYHA II to IV, after 6 weeks of optimal therapy | Referred | Eligible: ejection fraction 30 percent, NYHA II, three months of therapy, no hospital stay. Referred to a program that adapts training for wheelchair users with arm ergometry and resistance bands |
| Medication safety | Spironolactone and carvedilol safety | Each visit while titrating | Completed today | Potassium 4.6; no breast tenderness; heart rate 70 with no lightheadedness |
| Medication safety | Tobacco use and cessation treatment | Every visit | Completed today | Abstinent since April; patch course complete |
| Laboratory | HbA1c, urine albumin-creatinine ratio, and TSH | HbA1c and urine albumin yearly; TSH at diagnosis | Up to date | Drawn at diagnosis; the urine albumin test is repeated at the six-month review |
| Self-management | Home blood pressure and daily weight log; low-sodium diet | Every visit | Completed today | Log reviewed; weight-gain action plan given for the stop of furosemide |
Goal progress:
Guideline basis: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, heart failure and hypertension monographs (2026); Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021); USPSTF A and B Recommendations (2026)
Follow-up: Basic metabolic panel in one to two weeks after stopping furosemide. Six-month heart failure review with an echocardiogram, laboratory tests including a lipid panel, and the KCCQ-12. Next scheduled visit 1944-09-25: six-month heart failure review with repeat echocardiogram. [S]